Iron isomaltoside 1000
- Generic Name
- Iron isomaltoside 1000
- Drug Type
- Small Molecule
- CAS Number
- 1370654-58-2
- Unique Ingredient Identifier
- 3M6325NY1R
- Background
Iron isomaltoside 1000 is under investigation in Iron Deficiency Anaemia. Iron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.
- Associated Conditions
- Iron Deficiency (ID), Iron Deficiency Anemia (IDA)
CArdio PulmOnary Exercise Testing and IntRAvenous Iron- 'CAPOEIRA-I STUDY'
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2019-09-25
- Target Recruit Count
- 26
- Registration Number
- NCT03346213
- Locations
- 🇬🇧
University Hospital Southampton NHS Foundation trust, Southampton, England, United Kingdom
Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.
- Conditions
- Iron Deficiency Anemia of Pregnancy
- Interventions
- Drug: ferrous fumarate with ascorbic acid
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 201
- Registration Number
- NCT03188445
- Locations
- 🇩🇰
Phamacosmos Investigational site, Hvidovre, Sjaeland, Denmark
Efficacy of Intravenous Iron Therapy in Maintaining Hemoglobin Concentration on Patients Undergoing Bimaxillary Orthognathic Surgery
- Conditions
- RetrognathismFacial AsymmetryPrognathism
- Interventions
- Drug: Normal saline
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 58
- Registration Number
- NCT03094182
- Locations
- 🇰🇷
Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
HiFIT Study : Hip Fracture: Iron and Tranexamic Acid
- Conditions
- Hip Fractures PathologicAnemia
- Interventions
- Drug: Placebos tranexamic acid
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 419
- Registration Number
- NCT02972294
- Locations
- 🇫🇷
Chu Grenoble - Departement D'Anesthesie Reanimation, Grenoble, France
🇫🇷CHD Vendée, La Roche-sur-Yon, France
🇫🇷Hospices Civils Lyon, Lyon, France
A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer
- Conditions
- Anemia, Iron-Deficiency
- Interventions
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Universität des Saarlandes
- Target Recruit Count
- 26
- Registration Number
- NCT02905539
- Locations
- 🇩🇪
Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany
IV Iron Treatment of Restless Legs Syndrome
- Conditions
- Restless Legs Syndrome
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- Pharmacosmos A/S
- Registration Number
- NCT02484768
A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo
- Conditions
- Iron Deficiency Anemia
- Interventions
- Drug: Natrium Chloride 0,9%
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Pharmacosmos A/S
- Registration Number
- NCT02172001
Iron Replacement in Oesophagogastric Neoplasia
- First Posted Date
- 2013-08-22
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Nottingham University Hospitals NHS Trust
- Target Recruit Count
- 40
- Registration Number
- NCT01927328
- Locations
- 🇬🇧
Nottingham Univeristy Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom
Treatment of Women After Severe Postpartum Haemorrhage
- Conditions
- Severe Postpartum Haemorrhage
- Interventions
- Drug: Red blood cell transfusion
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 13
- Registration Number
- NCT01895205
Treatment of Women After Postpartum Haemorrhage
- Conditions
- Postpartum Haemorrhage
- Interventions
- Other: Standard medical Care
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 200
- Registration Number
- NCT01895218
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.